FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

NCT05217069 PHASE2 COMPLETED

Within the proposed single arm multicenter phase-II trial it is intended to investigate the feasi-bility of adding Avelumab to FOLFIRI plus Cetuximab after 4 cycles (2 months) of treatment with FOLFIRI plus Cetuximab. After 4 more cycles of FOLFIRI plus Cetuximab plus Avelumab the treatment will be de-escalated to Avelumab as a maintenance concept until progression of the disease according to RECIST 1.1 has occurred.

Details

Lead sponsor	Ludwig-Maximilians - University of Munich
Phase	PHASE2
Status	COMPLETED
Enrolment	57
Start date	Fri Sep 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Treatment Related Cancer

Interventions

• 5-FU
• Folinic Acid
• Irinotecan
• Cetuximab
• Avelumab

Countries

Germany